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was adapted to the Portuguese setting to evaluate the cost-effectiveness (CEA) of 
linezolid vs.vancomycin in MRSA cSSTI. Methods: Published Bayesian evidence 
synthesis results were used to populate efficacy parameters of the model. Resource 
utilization and MRSA prevalence rates were obtained through an expert panel of 
Portuguese clinicians and costs from published sources were applied to resource 
units. Analyses were done from the Portuguese NHS perspective. Both univariate 
and probabilistic sensitivity analyses were performed to test the robustness of model 
results. Results: Average cost per patient for linezolid and vancomycin treatments 
were 15,195€ and 17,345€ respectively. Average effectiveness gained with linezolid 
treatment was 0.002QALYs. Average saving obtained with linezolid treatment was 
2150€ per patient. ConClusions: Linezolid is a dominant strategy compared to 
vancomycin: less costly and more effective. Compared to vancomycin, linezolid is 
expected to result in lower total costs that offset its higher acquisition cost in cSSTI 
in Portugal.
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objeCtives: To assess the cost-effectiveness of ranibizumab compared to verteporfin 
in photodynamic therapy (vPDT) for the treatment of myopic choroidal neovasculari-
zation (mCNV) from the Canadian health care and societal perspectives. Methods: 
A Markov model was used to follow a cohort of 55-year old patients with mCNV over 
a lifetime horizon. The model included 8 health states based on best corrected visual 
acuity (BCVA) and an absorbing death state. Patients were allowed to remain in their 
current health state, or transition to other health states or death every 3 months. 
Results from the RADIANCE trial were used to inform the first year transitions for 
patients receiving ranibizumab, and the first 3 months for those on vPDT. The VIP 
trial was used to estimate month 4-12 transitions for vPDT. Patients transitioned 
according to natural progression from year 2 onwards. Health state utilities were 
derived from a Canadian utility study and published sources. Resource use and costs 
were collected from clinical trials, published literature, expert opinion, and standard 
Canadian sources. Results: From the health care perspective, patients receiving 
ranibizumab for mCNV incurred less health care costs compared to those on vPDT 
(cost savings of $3,939). This was achieved while accruing an additional 0.07 life years 
(LYs) and 0.37 quality-adjusted life years (QALYs). Thus ranibizumab dominated vPDT. 
Similar findings were observed from the societal perspective (cost saving of $14,217). 
The average BCVA score remained consistently higher with ranibizumab compared to 
vPDT over the entire time horizon. ConClusions: From a cost-effectiveness stand-
point, ranibizumab dominated vPDT in the treatment of mCNV, from both Canadian 
health care and societal perspectives. Patients on ranibizumab realized more QALYs 
and LYs at a lower cost compared to vPDT.
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objeCtives: Monthly dosing with ranibizumab (RBZ) is needed to achieve maxi-
mal sustained visual gains in patients with neovascular (“wet”) age-related macular 
degeneration (wAMD). In Sweden dosing is on an as-needed (PRN) basis, resulting in 
suboptimal efficacy. Intravitreal aflibercept dosed every 2 months (IVT-AFL) demon-
strated clinically equivalent efficacy compared to RBZ monthly dosing (RBZ Q4) in a 
randomized clinical trial setting. We assessed the cost-effectiveness of IVT-AFL vs. 
RBZ Q4 and RBZ PRN real-life data, in a Swedish setting. Methods: A Markov model 
compared wAMD treatment over two years with either IVT-AFL, RBZ Q4 or real-life 
RBZ PRN. Health states were based on visual acuity in the better-seeing eye; a propor-
tion discontinued treatment monthly or upon visual acuity < 20/400. Parameters were 
estimated from trial data, published literature, or expert opinion. Analyses were per-
formed from a societal perspective with a lifetime horizon (starting age 77 years). The 
model calculated costs (drug, administration, monitoring, vision impairment, adverse 
events, caregiver), quality-adjusted life-years (QALYs), and incremental cost-effec-
tiveness ratios (ICERs), all discounted 3% annually. Deterministic and probabilistic 
sensitivity analyses were performed. Results: IVT-AFL cost 578,400 SEK, compared 
with 686,600 SEK for RBZ Q4 and 565,700 SEK for real-life RBZ PRN; QALYs totaled 4.58 
for IVT-AFL, 4.59 for RBZ Q4, and 4.43 for real-life RBZ PRN. Compared with real-life 
RBZ PRN, IVT-AFL cost 80,000 SEK/QALY gained. RBZ Q4 cost over 20 million SEK/
QALY gained, compared with IVT-AFL Q8. The model was most sensitive to IVT-AFL 
efficacy and patient age. IVT-AFL had a 42% probability of dominating RBZ Q4 and a 
100% probability of being cost-effective vs. RBZ PRN, at an assumed willingness-to-pay 
threshold of 500,000 SEK. ConClusions: Results suggest that, in Sweden, attainment 
of maximal visual gains via IVT-AFL is cost-effective compared with real-life RBZ PRN 
dosing. RBZ Q4 is not cost-effective relative to IVT-AFL.
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objeCtives: To evaluate the cost-effectiveness of bimatoprost 0.03%/timolol 0.05% 
(BTFC) preservative-free (PF) fixed combination compared with dorzolamide/timolol 
costs. Drug acquisition cost for ustekinumab reflected the manufacturers’ UK Patient 
Access Scheme. Incremental cost-effectiveness ratios (ICERs) were calculated and 
treatments were ranked relative to supportive care. One-way sensitivity analyses, 
using alternative plausible values for key parameters, explored uncertainty in the 
results. Results: Infliximab provided the most additional quality-adjusted life-years 
(QALYs) vs. supportive care (0.186) followed by ustekinumab (0.174) and adalimumab 
(0.169). In the base case, adalimumab was the most cost-effective biologic (£19,082/
QALY vs. supportive care), followed by ustekinumab (£20,964/QALY), etanercept 25 mg 
BIW (£26,580/QALY), etanercept 50 mg BIW during the trial period followed by 25mg 
BIW (£28,719 per QALY), and infliximab (£46,844 per QALY). ICERs for ustekinumab 
and infliximab compared with adalimumab were £87,625 and £332,015, respectively. 
Adalimumab remained the most cost-effective in the majority of the sensitivity analy-
ses. ConClusions: In this decision-model analysis, adalimumab was the most cost-
effective biologic treatment for moderate to severe psoriasis in the UK.
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objeCtives: Ingenol mebutate gel is a recently developed, topical, 2 or 3 days patient-
administered AK therapy. The objective was to compare the cost-effectiveness of ingenol 
mebutate gel with diclofenac gel and other available therapies for the first-line treat-
ment of AK in adult patients, from the perspective of the National Health Service (NHS) 
in Scotland. Methods: A cost-utility analysis was conducted using a decision tree 
approach to calculate the costs and benefits of different treatment strategies for AK over 
a 12-month time horizon. Data on the relative efficacy of treatment was derived from a 
systematic review of RCTs and a subsequent mixed-treatment comparison (MTC). Utility 
scores and resource use data were obtained from published sources. Due to the uncer-
tainty surrounding the impact of AEs on HRQoL and costs, AEs were modelled in a sce-
nario analysis. Results: In the primary comparison, ingenol mebutate 150 mcg/g gel and 
500 mcg/g gel were associated with ICERs of £44 and £114 per QALY gained, respectively 
compared with diclofenac (3%) for 8 weeks and £36 and £74, respectively compared with 
diclofenac (3%) for 12 weeks. In the secondary comparisons, ingenol mebutate 150 mcg/g 
gel and 500 mcg/g gel were associated with ICERs of £47 and £134, respectively compared 
with 5-FU/salicylic acid (0.5%/10%) cutaneous solution and dominated cryotherapy (i.e. 
were cheaper and more effective). Ingenol mebutate 150 mcg/g gel and 500 mcg/g gel were 
cheaper and less effective than 5-FU (5%) cream. Ingenol mebutate 150 mcg/g gel, but not 
ingenol mebutate 500 mcg/g gel, was cost-effective assuming a decision making will-
ingness-to-pay threshold of £20,000/QALY (for one additional QALY gained, there would 
be an incremental cost of £26,525 incurred for 5-FU (5%) cream vs ingenol mebu-
tate gel). ConClusions: Ingenol mebutate gel is a fast-acting, convenient 
and, relative to most comparators, cost-effective therapy for the first-line treatment 
of AK.
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objeCtives: To determine if providing high dose anti-oxidant vitamins + Zinc 
treatment to intermediate Age Related Macular Degeneration (AMD) patients 
aged 40-79 years from Singapore is cost effective in preventing progression to Wet 
AMD. Methods: We estimated the number of AMD patients aged 40 to 79 years 
(Category 3 and 4) in the Singaporean resident population. This hypothetical cohort 
was followed for 5 calendar years to determine the number of patients who would 
progress to wet AMD given the following four treatment scenarios: a) Vitamins 
+Zn followed by Ranibizumab (as needed) for wet AMD; b) Placebo followed by 
Ranibizumab (as needed) for wet AMD; c) Vitamins + Zn followed by Bevacizumab 
(monthly) for wet AMD; and d) Placebo followed by Bevacizumab (monthly) for wet 
AMD. Costs were estimated for the above scenarios from the providers’ perspective 
and cost effectiveness was measured by cost per disability adjusted life year (DALY) 
averted with a disability weight of 0.22 for wet AMD. Crude annual mortality rate 
was incorporated into the model. Results: Over 5400 patients could be prevented 
from progressing to Wet AMD cumulatively over five years if preventive anti-oxidant 
vitamins +Zn treatment were prescribed. Vitamins + Zn followed by ranibizumab 
(as needed) or bevacizumab (monthly) was cost effective compared to placebo fol-
lowed by either drug (cost per DALY averted: $1885.8 - well within the threshold 
suggesting it is cost effective). However, bevacizumab (monthly 1 injection) alone 
was cost effective. Cost savings as a result of prescribing anti-oxidant vitamins +Zn 
were $ 46.7M for ranibizumab arm over 5 years. ConClusions: Prophylactic treat-
ment with high dose anti-oxidant vitamins + Zn for intermediate AMD patients, 
followed by ranibizumab for patients who progressed to wet AMD was found to be 
cost-effective. These findings have implications for intermediate AMD screening, 
treatment and health care planning in Singapore.
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objeCtives: Methicillin-resistant Staphylococcus aureus (MRSA) complicated skin 
and soft-tissue infection (cSSTI) is an infection associated with high health expendi-
ture for the Portuguese National Health Service (NHS). A decision analytic model 
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objeCtives: The value of ranibizumab monotherapy and laser combination therapy 
compared to laser photocoagulation was assessed within the framework of a cost-
utility analysis from the Quebec health care and societal perspectives. Methods: 
A Markov model followed a cohort of patients with diabetic macular edema over 
a lifetime time horizon. The model included 8 heath states as defined by best-
corrected visual acuity and one absorbing state for death. All transition probabilities 
in Year 1 were based on the RESTORE trial. For Years 2 and 3 data from the RESTORE 
Extension trial was used to inform ranibizumab monotherapy and combination 
therapy transition probabilities. For laser photocoagulation, Years 2 and 3 transition 
probabilities were based on data from DRCR.net trials. From Year 4 onwards, all tran-
sition probabilities were based on the natural history of disease. Health state utilities 
were derived from the literature (for the best-seeing eye) and a Canadian utility 
study in RVO patients (for the worse-seeing eye). Resource use and costs were col-
lected from published literature and standard Quebec sources. Costs and outcomes 
were discounted at 5% as recommended by Canadian guidelines. Results: From 
the health care perspective, patients receiving ranibizumab monotherapy accrued 
an additional 0.40 quality-adjusted life years (QALYs) and an incremental cost of 
CAD$9,790, resulting in $24,345 per QALY gained. Patients receiving combination 
therapy accrued an additional 0.32 QALYS and an incremental cost of $11,387, result-
ing in $36,148 per QALY gained. At a willingness-to-pay threshold of $50,000, ranibi-
zumab monotherapy and combination therapy had a 75.2% and 59.3% probability 
of being cost-effective (CE), respectively. From the societal perspective, considering 
costs from productivity losses, ranibizumab monotherapy and combination therapy 
dominated laser photocoagulation and had an 88.2% and 78.8% probability of being 
CE, respectively. ConClusions: Compared to laser photocoagulation, ranibizumab 
monotherapy and combination therapy for 3 years show cost-effectiveness from 
health care and societal perspectives.
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objeCtives: To calculate the cost-effectiveness of ranibizumab versus licensed 
comparators in wet age-related macular degeneration (AMD) from a French soci-
etal perspective based on real-life observational data. Methods: A Markov model 
was developed containing 5 health states defined by visual acuity (VA) of the 
treated eye and a death state. The model time horizon covered 2 years of treat-
ment followed by 8 years of best supportive care (BSC). Medical and non-medical 
resource use and efficacy during treatment were based on observational patient-
level data with ranibizumab (LUEUR and LUMIERE studies) or verteporfin (OPV 
study). No observational data were available for pegaptanib. Efficacy was obtained 
per VA level to control for population differences in baseline VA. The base-case 
analysis reflects 1st line therapy. Mutual to both comparators, BSC was modelled 
with clinical trial placebo data and resource use estimates. Annual discount rates 
were 4% for costs (€ 2011) and outcomes. Utilities reflected general population 
preference (UK) using time-trade-off methods. Results: Compared to verteporfin, 
1st line ranibizumab provided a gain of 0.20 QALYs and avoided 0.63 years of 
vision impairment (YVI). The total incremental cost was € 3,843. The cost-utility 
was € 19,088/QALY, the cost per YVI avoided was € 6,114. Similar outcomes were 
obtained when including pre-treated patients. Ranibizumab was cost-effective 
with a probability of 62.8% and 78.2% at willingness to pay thresholds of € 20,000/
QALY and € 30,000/QALY respectively. ConClusions: Based on real-life observa-
tional studies, 2-year treatment with ranibizumab was associated with improved 
vision-related health outcomes and a cost-utility ratio below commonly applied 
willingness to pay thresholds.
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bACkgRound: Little is known about the health-economic properties of sequences 
of biologics agents for the treatment of moderate-to-severe psoriasis. These are 
available to patients who have failed to achieve therapeutic goals on the tradi-
tional systemics such as methotrexate and ciclosporin. objeCtives: To predict 
the five-year costs and health outcomes associated with different sequences of 
biologic psoriasis treatments (adalimumab, etanercept, infliximab, and usteki-
numab), and to evaluate their cost-effectiveness from a Finnish societal per-
spective. Methods: The Psoriasis Area Severity Index (PASI) was chosen as the 
main efficacy measure and results of a published meta-analysis were re-run 
to provide relative efficacy of the biologics in the short term. A fully stochas-
tic Markov cohort model was developed that represents patient health in terms 
of PASI, Dermatology Life Quality Index (DLQI), and quality-adjusted life-years 
(QALY). Failure to achieve efficacy targets, serious adverse events and other rea-
sons of withdrawal led to switch to the next treatment in the sequence, and 
eventually methotrexate maintenance. Costs included direct medical and related 
direct costs as well as productivity losses. Costs and QALYs were discounted at 
3% per annum. Results: At a willingness-to-pay threshold of EUR 50,000 per 
QALY gained, only four of the 60 potential sequences had non-zero probability of 
being cost-effective. The sequence most likely to be cost-effective was first-line 
ustekinumab followed by adalimumab followed by maintenance. Its incremental 
cost-effectiveness ratio (ICER) per QALY gained relative to the cheapest sequence 
(etanercept followed by adalimumab) was estimated at EUR 8,253. Some model-
ling assumptions tested in the sensitivity analyses may be influential in driving 
the results, but others, for example inclusion of an anti-TNF class effect, made 
PF fixed combination (DTFC PF), and tafluprost PF/timolol PF unfixed-combination 
(TTUF PF) for the treatment of primary open-angle glaucoma (POAG). Methods: A 
cost-effectiveness and cost-utility model was developed to estimate lifetime costs 
and outcomes. The analysis was performed from a UK NHS perspective. No head-to-
head evidence was available for BTFC PF and the comparators; therefore effectiveness 
estimates in terms of the mean lowering of intraocular pressure (IOP) at Week 12 
were estimated using a mixed treatment comparison (MTC). Estimates of visual field 
progression were taken from the literature and modelled by an irreversible decrease 
in patients’ mean deviation (MD) score in each 12-week cycle. Resource use levels for 
each of the health states were obtained using a clinician survey. All costs and utili-
ties were obtained from literature or NHS cost sources. Outcomes were reported in 
terms of cost per mmHg IOP gained and cost per quality-adjusted-life-year (QALY). 
Deterministic and probabilistic sensitivity analyses were performed. Results: The 
cost-effectiveness results indicated that BTFC PF dominates DTFC PF and TTUF PF, 
with patients treated with BTFC PF having a greater IOP reduction (1.6 mmHg) and 
incurring lower lifetime costs (£2,294 vs. DTFC PF, £2,919 vs. TTUF PF). The cost-utility 
results indicate BTFC PF dominates DTFC PF and TTUF as well with an incremen-
tal gain of 0.03 QALYs. Deterministic sensitivity analyses indicate the results are 
most sensitive to the rate of visual field progression. Probabilistic sensitivity analysis 
indicates that BTFC PF has a 98.8% probability of being cost-effective at a threshold 
of £20,000/QALY. ConClusions: BTFC PF is considered a cost-effective treatment 
option for the treatment of POAG when compared with DTFC PF and TTUF PF from 
a UK NHS perspective.
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objeCtives: Anti-VEGF therapy improves visual acuity in patients with neovascu-
lar (“wet”) age-related macular degeneration (wAMD). By comparing different treat-
ment regimen scenarios, based on data from available randomized clinical studies, 
the objective was to compare costs for intravitreal aflibercept (IVT-AFL) treatment 
with Ranibizumab treatment when treating wAMD patients in a Spanish set-
ting. Methods: A Markov model, describing wAMD treatment was estimated, cal-
culating the direct medical costs based on 2-year clinical trial data. Parameters were 
estimated from trial data, published literature, and expert opinion. Costs, discounted 
at 3% per year, were calculated over a five-year horizon. Alternative scenarios and 
deterministic sensitivity analyses were performed and reported. Results: IVT-AFL, 
dosed every two months in Year 1 and modified quarterly dosing in year two, was 
least expensive, € 13,519, followed by IVT-AFL every second month, for two years, 
€ 16,085. Cost of Ranibizumab monthly (RBZ Q4) regimens ranged from € 17,284 (12.6 
injections over two years) to € 26,457 (monthly injections over two years). Results 
were driven by less frequent IVT-AFL dosing and monitoring. The model was most 
sensitive to RBZ Q4 Year 1 efficacy and Year 2 injection frequency. ConClusions: 
IVT-AFL is less expensive than Ranibizumab when treating wAMD in Spain, due to 
less frequent dosing with IVT-AFL and lower monitoring costs.
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objeCtives: To model the lifetime cost attributed to intraocular lenses (multifo-
cal vs. monofocal) implantation during cataract surgery from patient’s perspec-
tive. Methods: The Markov model was developed with 28-day cycle length 
projecting life-time costs of patients undergoing cataract surgery of both eyes at 65 
years. Patients move among four health states which occur after cataract surgery. 
Patients become independent on the spectacles or need them after cataract surgery 
with probabilities derived from literature. In the model, we assume that new glasses 
are bought by patients, who wear glasses after surgery, every three years. Patient 
may die from each health state with probability derived from Czech life-tables there 
was no difference in mortality specific for particular intraocular lenses. Resource 
utilization was received by an expert panel and unit costs were derived from current 
pricing list. Costs of cataract surgery with multifocal and monofocal lenses implanta-
tion were 1,200EUR and 9.9EUR, respectively. Mean costs of spectacles were 48.9EUR 
and 82.5EUR after the intervention of implanting multifocal and monofocal lenses, 
respectively and monthly costs of ophthalmologist visit, maintenance and service 
of spectacles was 0.4EUR. Discount rate of 3% was applied. One-Way Sensitivity 
Analysis was performed. Results: After cataract surgery with multifocal lenses 
implantation, patients purchase on average by 4.4 spectacles less compare to patients 
undergoing monofocal intraocular lenses implantation (i.e. 5.9). The initial patient’s 
investment of 1,190EUR into multifocal IOLs is in the lifetime horizon partially off-
set by saving of 364EUR attributed to lower number of new spectacles purchased 
and their maintenance. Costs on spectacles after cataract surgery with monofocal 
lenses and level of reimbursement of multifocal lenses were the biggest driver of the 
results. ConClusions: Bilateral multifocal IOL implants decrease patient’s depend-
ence on spectacles. From patient’s perspective, the initial investment into multifocal 
lenses is partially compensated by saving of spectacles costs and its maintenance.
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